Evolus, Inc.
EOLS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001570562
In the last 90 days, Evolus, Inc. insiders filed 0 open-market purchases and 1 sale; 158 institutions reported holding it in 13F filings for Q2 2026, worth $335.1M in total; no superinvestor holds it.
Holders of 5% or more of EOLS
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Evolus, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Lynch Timothy P | 13G/A | 9.90%6.43M shares | +2.00 ppfrom 7.90% | Aug 18, 20253 filings | Feb 17, 2026 | SEC |
| Nantahala Capital Management, LLC | 13G/A | 8.85%5.73M shares | +2.95 ppfrom 5.90% | Nov 14, 20243 filings | Nov 14, 2025 | SEC |
| BlackRock, Inc. | 13G/A | 6.90%4.36M shares | – | Feb 5, 20251 filing | Feb 5, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
16 Schedule 13D and 13G filings on Evolus, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Mar 26, 202611:30 AM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | –Below 5% | Mar 13, 2026 | SEC |
| Feb 17, 20264:56 PM ET | Caligan Partners LPand 1 other | 13G/A | 0.00%0 shares | −6.40 ppfrom 6.40%Below 5% | Dec 31, 2025 | SEC |
| Feb 17, 20264:15 PM ET | Tang Capital Management LLCand 5 others | 13G/A | 1.92%1.25M shares | −5.98 ppfrom 7.90%Below 5% | Dec 31, 2025 | SEC |
| Feb 17, 202612:25 PM ET | Lynch Timothy P | 13G/A | 9.90%6.43M shares | +2.00 ppfrom 7.90% | Dec 31, 2025 | SEC |
| Nov 14, 20254:43 PM ET | Nantahala Capital Management, LLCand 2 others | 13G/A | 8.85%5.73M shares | +2.95 ppfrom 5.90% | Sep 30, 2025 | SEC |
| Nov 14, 20252:30 PM ET | Caligan Partners LPand 1 other | 13G/A | 6.40%4.14M shares | +1.20 ppfrom 5.20% | Sep 30, 2025 | SEC |
| Nov 14, 20251:37 PM ET | Lynch Timothy P | 13G/A | 7.90%5.13M shares | +1.60 ppfrom 6.30% | Sep 30, 2025 | SEC |
| Aug 18, 202512:11 PM ET | Lynch Timothy P | 13G | 6.30%4.09M shares | New | Aug 11, 2025 | SEC |
| Aug 14, 20254:23 PM ET | Perceptive Advisors LLCand 2 others | 13G/A | 3.80%2.47M shares | −2.60 ppfrom 6.40%Below 5% | Jun 30, 2025 | SEC |
| Aug 14, 20254:15 PM ET | Caligan Partners LPand 1 other | 13G | 5.20%3.34M shares | New | Jun 30, 2025 | SEC |
| May 15, 20254:47 PM ET | Nantahala Capital Management, LLCand 2 others | 13G | 5.90%3.75M shares | +1.42 ppfrom 4.48% | Mar 31, 2025 | SEC |
| May 15, 20254:30 PM ET | Perceptive Advisors LLCand 2 others | 13G/A | 6.40%4.13M shares | – | Mar 31, 2025 | SEC |
| May 15, 20254:15 PM ET | Tang Capital Management LLCand 5 others | 13G/A | 7.90%5.00M shares | – | Mar 31, 2025 | SEC |
| Feb 6, 20254:16 PM ET | Medytox Inc. | 13G/A | 3.40%2.14M shares | –Below 5% | Dec 31, 2024 | SEC |
| Feb 5, 20251:23 PM ET | BlackRock, Inc. | 13G/A | 6.90%4.36M shares | – | Dec 31, 2024 | SEC |
| Nov 14, 20244:53 PM ET | Nantahala Capital Management, LLCand 2 others | 13G/A | 4.48%2.82M shares | –Below 5% | Sep 30, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Evolus, Inc. shares.
No Form 144 notices for Evolus, Inc. are on file.